Crucially, cell-permeable analogue 3 induces selectivecell viability reduction of p53-Y220C cancer cell lines HUH-7 (liver),BXPC-3 (pancreas), and NUGC-3 (stomach), while maintaining comparativelylow toxicity in the same concentration range in representative cancerlines NUGC-4 (stomach, p53 WT), SW1088 (brain, p53-R273C), WI38 (humanfibroblasts, p53-WT), along with in house CRISPR-engineered HUH-7p53-Y220C KO cells. This evidence concerns the gene TP53 and cancer.